This Article Figures Only Full Text Full Text (PDF) View Participating Centers and Appendices All Versions of this Article: j.jacc.2007.02.065v1 49/25/2398    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giugliano, R. P. Search for Related Content PubMed PubMed Citation Articles by Giugliano, R. P.

CLINICAL RESEARCH

Recombinant Nematode Anticoagulant Protein c2 in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

The ANTHEM–TIMI-32 Trial

Robert P. Giugliano, MD, SM, FACC^_*,_*, Stephen D. Wiviott, MD^_*, Peter H. Stone, MD, FACC, Daniel I. Simon, MD, PhD, FACC, Marc J. Schweiger, MD, FACC, Alain Bouchard, MD, FACC^||, Massoud A. Leesar, MD, FACC^#, Michael A. Goulder, BSc^_**, Steven R. Deitcher, MD, Carolyn H. McCabe, BS^_*, Eugene Braunwald, MD, MACC^_* for the ANTHEM–TIMI-32 Investigators

^_* TIMI Study Group
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts
University Hospitals–Case Medical Center, Cleveland, Ohio
Baystate Medical Center, Springfield, Massachusetts
^|| Baptist Medical Center-Princeton, Birmingham, Alabama
^# University of Louisville, Louisville, Kentucky
^_** Nottingham Clinical Research, Nottingham, United Kingdom
Nuvelo, Inc., San Carlos, California

Manuscript received January 3, 2007; revised manuscript received January 31, 2007, accepted February 12, 2007.

^_* Reprint requests and correspondence: Dr. Robert P. Giugliano, TIMI Study Group, 350 Longwood Avenue, First Floor Offices, Boston, Massachusetts 02115 (Email: rgiugliano{at}partners.org).

Objectives: We sought to evaluate the safety and efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non–ST-segment elevation acute coronary syndrome (nSTE-ACS).

Background: Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex that has the potential to reduce ischemic complications mediated by thrombin generation.

Methods: A total of 203 patients were randomized 4:1 to double-blinded intravenous rNAPc2 or placebo every 48 h for a total of 1 to 3 doses in 8 ascending panels (1.5 to 10 µg/kg). All patients received aspirin, unfractionated heparin (UFH), or enoxaparin and early catheterization; clopidogrel and glycoprotein IIb/IIIa blockers were encouraged. Two subsequent open-label panels evaluated 10 µg/kg rNAPc2 with half-dose UFH (n = 26) and no UFH (n = 26). The primary end point was the rate of major plus minor bleeding. Pharmacokinetics, pharmacodynamics, continuous electrocardiography, and clinical events were assessed.

Results: Recombinant NAPc2 did not significantly increase major plus minor bleeding (3.7% vs. 2.5%; p = NS) despite increasing the international normalized ratio in a dose-related fashion (trend p 0.0001). Higher-dose rNAPc2 (7.5 µg/kg) suppressed prothrombin fragment F1.2 generation compared with placebo and reduced ischemia by >50% compared to placebo and lower-dose rNAPc2. Thrombotic bailout requiring open-label anticoagulant occurred in 5 of 26 patients treated without UFH, but none in the half-dose UFH group (19% vs. 0%; p = 0.051).

Conclusions: In patients with nSTE-ACS managed with standard antithrombotics and an early invasive approach, additional proximal inhibition of the coagulation cascade with rNAPc2 was well tolerated. rNAPc2 doses 7.5 µg/kg suppressed F1.2 and reduced ischemia, though some heparin may be necessary to avoid procedure-related thrombus formation. (Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32; http://www.clinicaltrial.gov/ct/show/NCT00116012?order=1; NCT00116012 [ClinicalTrials.gov] )

Abbreviations and Acronyms   CABG = coronary artery bypass graft   F1.2 = prothrombin fragment 1.2   GP = glycoprotein   INR = international normalized ratio   nSTE-ACS = non–ST-segment elevation acute coronary syndrome   PCI = percutaneous coronary intervention   rNAPc2 = recombinant nematode anticoagulant protein c2   TF/fVIIa = tissue factor/activated factor VII   TIMI = Thrombolysis In Myocardial Infarction   UFH = unfractionated heparin

This article has been cited by other articles:

				J. I. Weitz, J. W. Eikelboom, and M. M. Samama New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e120S - e151S. [Abstract] [Full Text] [PDF]

				S. S. Basra, P. Tsai, and N. M. Lakkis Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2263 - 2269. [Abstract] [Full Text] [PDF]

				A. Gomez-Outes, M. L. Suarez-Gea, R. Lecumberri, E. Rocha, C. Pozo-Hernandez, and E. Vargas-Castrillon New parenteral anticoagulants in development Therapeutic Advances in Cardiovascular Disease, February 1, 2011; 5(1): 33 - 59. [Abstract] [PDF]

				M. Singh, S. Adigopula, P. Patel, K. Kiran, and S. Khosla Recent advances in oral anticoagulation for atrial fibrillation Therapeutic Advances in Cardiovascular Disease, December 1, 2010; 4(6): 395 - 407. [Abstract] [PDF]

				M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano Antithrombotics in Acute Coronary Syndromes J. Am. Coll. Cardiol., September 8, 2009; 54(11): 969 - 984. [Abstract] [Full Text] [PDF]